stockrowNovartis AG
NVS Healthcare Drug Manufacturers General
Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024.
- Revenue
- +4.67%
- EPS
- −69.1%
- Free cash flow
- −17.8%
- Total debt
- +53.9%
Quarter to September 2026, against a year earlier
Follow NVS
Alert me
Novartis AG (NVS) EV/Sales
As of 5 November 2026, Novartis AG (NVS) trades at a EV/Sales of 6.0×. Over the past ten years it has ranged from 3.2× (September 2022) to 6.2× (September 2026); the current reading is higher than 99% of that period. That is above the Drug Manufacturers General industry median of 4.1× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.1× | 24.23% |
| FY2024 | 4.1× | (12.84%) |
| FY2023 | 4.7× | 1.52% |
| FY2022 | 4.6× | 28.78% |
| FY2021 | 3.6× | (22.61%) |
| FY2020 | 4.7× | 0.43% |
| FY2019 | 4.6× | 2.48% |
| FY2018 | 4.5× | 7.44% |
| FY2017 | 4.2× | 13.63% |
| FY2016 | 3.7× | (7.39%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 5.4× | (10.02%) |
| Jun 2026 | 6.0× | 2.30% |
| Mar 2026 | 5.8× | 14.16% |
| Dec 2025 | 5.1× | 7.62% |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PFE Pfizer Inc. compare | 3.4× |
| NVO Novo Nordisk A/S compare | 3.8× |
| AZN AstraZeneca PLC compare | 5.0× |
| NVS Novartis AG | 6.0× |
| MRK Merck & Co., Inc. compare | 6.0× |
| JNJ Johnson & Johnson compare | 6.8× |
| GILD Gilead Sciences, Inc. compare | 7.4× |
| AMGN Amgen Inc. compare | 7.5× |
| ABBV AbbVie Inc. compare | 8.8× |
| Drug Manufacturers General industry median | 4.1× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on NVS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement